Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidino functionality

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 3, 2011, Pages 313-323

  Sun, Jing ^a   Miller, Jonathan M ^a   Beig, Avital ^b   Rozen, Liat ^b   Amidon, Gordon L ^a   Dahan, Arik ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

guanidino containing drugs; intestinal permeability; ion pair approach; nanocarriers; oral drug absorption; prodrug approach

Indexed keywords

1 HYDROXY 2 NAPHTHOIC ACID; 2 NAPHTHOIC ACID DERIVATIVE; [3 (HYDROXYMETHYL)PHENYL]GUANIDINE; ARGATROBAN; ARGININE; CARBAMIC ACID DERIVATIVE; CHITOSAN; CIMETIDINE; DABIGATRAN; FAMOTIDINE; GUANFACINE; GUANIDINE DERIVATIVE; METFORMIN; METOPROLOL; NANOCARRIER; NANOPARTICLE; OSELTAMIVIR; POLYGLACTIN; PRODRUG; STREPTOMYCIN; UNCLASSIFIED DRUG; ZANAMIVIR;

ACTIVE TRANSPORT; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG STRUCTURE; ENDOCYTOSIS; HUMAN; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LIPOPHILICITY; NONHUMAN; PASSIVE TRANSPORT; PKA; REVIEW; TRANSCYTOSIS;

ANIMALS; BIOLOGICAL AVAILABILITY; GUANIDINES; HUMANS; INTESTINAL ABSORPTION; PHARMACEUTICAL PREPARATIONS;

EID: 79951928274     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.550875     Document Type: Review

References (81)

1. Mori A. Biochemistry and neurotoxicology of guanidino compounds. History and recent advances. Pavlov J Biol Sci 1987;22(3):85-94
2. Hiramatsu M. A role for guanidino compounds in the brain. Mol Cell Biochem 2003;244(1-2):57-62 (Pubitemid 36411053)
3. Taes YE, Marescau B, De Vriese A, et al. Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status. Nephrol Dial Transplant 2008;23(4):1330-5 (Pubitemid 351767509)
4. De Deyn PP, Vanholder R, Eloot S, et al. Guanidino compounds as uremic (neuro)toxins. Semin Dial 2009;22(4):340-5
5. Greenhill JV, Lue P. Amidines and guanidines in medicinal chemistry. Prog Med Chem 1993;30:203-326
6. Berlinck RG, Burtoloso AC, Kossuga MH. The chemistry and biology of organic guanidine derivatives. Nat Prod Rep 2008;25(5):919-54
7. Morris Jr SM. Enzymes of arginine metabolism. J Nutr 2004;134(Suppl 10):2743S-2747S; discussion 65S-67S (Pubitemid 39315214)
8. Masic LP. Arginine mimetic structures in biologically active antagonists and inhibitors. Curr Med Chem 2006;13(30):3627-48 (Pubitemid 44882612)
9. Closs EI, Simon A, Vekony N, et al. Plasma membrane transporters for arginine. J Nutr 2004;134(Suppl 10):2752S-2759S, disscussion 2765S-2767S (Pubitemid 39315216)
10. Broer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev 2008;88(1):249-86
11. Kiechel JR. Pharmacokinetics and metabolism of guanfacine in man: a review. Br J Clin Pharmacol 1980;10(Suppl 1):25S-32S (Pubitemid 10065106)
12. Palm K, Luthman K, Ros J, et al. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J Pharmacol Exp Ther 1999;291(2):435-43
13. Islam MS, Narurkar MM. Solubility, stability and ionization behaviour of famotidine. J Pharm Pharmacol 1993;45(8):682-6 (Pubitemid 23258682)
14. Dahan A, Miller JM, Hilfinger JM, et al. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm 2010;7(5):1827-34
15. Zhou SY, Piyapolrungroj N, Pao L, et al. Regulation of paracellular absorption of cimetidine and 5-aminosalicylate in rat intestine. Pharm Res 1999;16(11):1781-5 (Pubitemid 29530414)
16. Mahato RI, Narang AS, Thoma L, et al. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 2003;20(2-3):153-214 (Pubitemid 37237279)
17. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005;19(3):165-77 (Pubitemid 40994232)
18. Chremos AN. Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol 1987;9(Suppl 2):7-12 (Pubitemid 17118612)
19. Lee K, Thakker DR. Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J Pharm Sci 1999;88(7):680-7 (Pubitemid 29325994)
20. Bourdet DL, Pritchard JB, Thakker DR. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther 2005;315(3):1288-97
21. Lee K, Ng C, Brouwer KL, et al. Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers. J Pharmacol Exp Ther 2002;303(2):574-80 (Pubitemid 35231228)
22. Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm 2009;6(1):19-28
23. Dahan A, Sabit H, Amidon GL. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of P-gp and MRP2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 2009;37(10):2028-36
24. Dahan A, Amidon G. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of P-glycoprotein. Pharm Res 2009;26(4):883-92
25. Dahan A, Amidon GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 2009;297(2):G371-7
26. Dahan A, Amidon GL. MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm 2010;386(1-2):216-20
27. Dahan A, Sabit H, Amidon G. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J 2009;11(2):205-13
28. Dahan A, West BT, Amidon GL. Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci 2009;36(2-3):320-9
29. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979;16(3):195-202 (Pubitemid 10227380)
30. Nicklin P, Keates AC, Page T, et al. Transfer of metformin across monolayers of human intestinal Caco-2 cells and across rat intestine. Int J Pharm 1996;128(1-2):155-62 (Pubitemid 26091018)
31. Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20(5):379-86
32. Dresser MJ, Xiao G, Leabman MK, et al. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 2002;19(8):1244-7 (Pubitemid 34985011)
33. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007;35(10):1956-62 (Pubitemid 47481592)
34. Huttunen KM, Mannila A, Laine K, et al. The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption. J Med Chem 2009;52(14):4142-8
35. Linkins LA, Weitz JI. Pharmacology and clinical potential of direct thrombin inhibitors. Curr Pharm Des 2005;11(30):3877-84 (Pubitemid 41632243)
36. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999;36(Suppl 1):1-11 (Pubitemid 29322452)
37. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999;37(6):471-84 (Pubitemid 30032251)
38. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010;328(5983):1272-5
39. Ottmann M, Duchamp MB, Casalegno JS, et al. Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance. Antivir Ther 2010;15(5):721-6
40. Li W, Escarpe PA, Eisenberg EJ, et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998;42(3):647-53 (Pubitemid 28114822)
41. Young D, Fowler C, Bush K. RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza. Philos Trans R Soc Lond B Biol Sci 2001;356(1416):1905- 13 (Pubitemid 34099097)
42. Ettmayer P, Amidon GL, Clement B, et al. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004;47(10):2393-404 (Pubitemid 38580074)
43. Hsieh PW, Hung CF, Fang JY. Current prodrug design for drug discovery. Curr Pharm Des 2009;15(19):2236-50
44. Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2000;2(1):E6
45. Majumdar S, Duvvuri S, Mitra AK. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv Drug Deliv Rev 2004;56(10):1437-52 (Pubitemid 38748825)
46. Saulnier MG, Frennesson DB, Deshpande MS, et al. An efficient method for the synthesis of guanidino prodrugs. Bioorg Med Chem Lett 1994;4(16):1985-90 (Pubitemid 24265304)
47. Humphreys WG, Obermeier MT, Chong S, et al. Oxidative activation of acylguanidine prodrugs: intestinal presystemic activation in rats limits absorption and can be inhibited by co-administration of ketoconazole. Xenobiotica 2003;33(1):93-106 (Pubitemid 36071766)
48. Arafa RK, Brun R, Wenzler T, et al. Synthesis, DNA affinity, and antiprotozoal activity of fused ring dicationic compounds and their prodrugs. J Med Chem 2005;48(17):5480-8 (Pubitemid 41209245)
49. Maryanoff BE, McComsey DF, Costanzo MJ, et al. Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa. Chem Biol Drug Des 2006;68(1):29-36 (Pubitemid 44272816)
50. Arafa RK, Ismail MA, Munde M, et al. Novel linear triaryl guanidines, N-substituted guanidines and potential prodrugs as antiprotozoal agents. Eur J Med Chem 2008;43(12):2901-8
51. Huttunen KM, Leppanen J, Kemppainen E, et al. Towards metformin prodrugs. Synthesis 2008;(22):3619-24
52. Peterlin-Masic L, Cesar J, Zega A. Metabolism-directed optimisation of antithrombotics: the prodrug principle. Curr Pharm Des 2006;12(1):73-91
53. Midgley I, Fitzpatrick K, Taylor LM, et al. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl] furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/ antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride). Drug Metab Dispos 2007;35(6):955-67 (Pubitemid 46798606)
54. Clement B. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev 2002;34(3):565-79 (Pubitemid 35006065)
55. Clement B, Mau S, Deters S, et al. Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino) iminomethyl]benzoyl]amino]-1- oxopropyl]-4- piperidinyl]oxy]-acetic acid). Drug Metab Dispos 2005;33(11):1740-7
56. Brandsch M, Knutter I, Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 2008;60(5):543-85 (Pubitemid 351589044)
57. Soul-Lawton J, Seaber E, On N, et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;39(12):2759-64
58. Balimane PV, Tamai I, Guo A, et al. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 1998;250(2):246-51 (Pubitemid 28463863)
59. Sun J, Dahan A, Amidon GL. Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J Med Chem 2010;53(2):624-32
60. Sun J, Dahan A, Walls Z, et al. Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect. Mol Pharm 2010;7(6):2362-8
61. Miller JM, Dahan A, Gupta D, et al. Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs. J Control Release 2009;137(1):31-7
62. Miller JM, Dahan A, Gupta D, et al. Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm 2010;7(4):1223-34
63. Jaimini M, Rana AC, Tanwar YS. Formulation and evaluation of famotidine floating tablets. Curr Drug Deliv 2007;4(1):51-5 (Pubitemid 46066414)
64. Elmowafy EM, Awad GA, Mansour S, et al. Release mechanisms behind polysaccharides-based famotidine controlled release matrix tablets. AAPS PharmSciTech 2008;9(4):1230-9
65. Gupta R, Pathak K. Optimization studies on floating multiparticulate gastroretentive drug delivery system of famotidine. Drug Dev Ind Pharm 2008;34(11):1201-8
66. Ramachandran S, Shaheedha SM, Thirumurugan G, et al. Floating controlled drug delivery system of famotidine loaded hollow microspheres (microballoons) in the stomach. Curr Drug Deliv 2010;7(1):93-7
67. Guan J, Zhou L, Nie S, et al. A novel gastric-resident osmotic pump tablet: in vitro and in vivo evaluation. Int J Pharm 2010;383(1-2):30-6
68. Guan J, Zhou L, Pan Y, et al. A novel gastro-retentive osmotic pump capsule using asymmetric membrane technology: in vitro and in vivo evaluation. Pharm Res 2010;27(1):105-14
69. Pentikainen PJ. Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products. Int J Clin Pharmacol Ther Toxicol 1986;24(4):213-20 (Pubitemid 16113669)
70. Stepensky D, Friedman M, Srour W, et al. Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. J Control Release 2001;71(1):107-15 (Pubitemid 32195445)
71. Gusler G, Gorsline J, Levy G, et al. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol 2001;41(6):655-61 (Pubitemid 32493360)
72. Di Colo G, Falchi S, Zambito Y. In vitro evaluation of a system for pH-controlled peroral delivery of metformin. J Control Release 2002;80(1-3):119-28 (Pubitemid 34273753)
73. Timmins P, Donahue S, Meeker J, et al. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005;44(7):721-9 (Pubitemid 40994081)
74. Di Colo G, Zambito Y, Baggiani A, et al. A site-specific controlled-release system for metformin. J Pharm Pharmacol 2005;57(5):565-71 (Pubitemid 40562395)
75. Li J, Jin Y, Wang TY, et al. Relative bioavailability and bioequivalence of metforphin hydrochloride extended-released and immediate-released tablets in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet 2007;32(1):21-8 (Pubitemid 46649807)
76. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. J Anat 1996;189(Pt 3):503-5 (Pubitemid 27011002)
77. Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev 2001;50(Suppl 1):S69-89 (Pubitemid 32905356)
78. Lu JM, Wang X, Marin-Muller C, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009;9(4):325-41
79. Pandey R, Khuller GK. Nanoparticle-based oral drug delivery system for an injectable antibiotic - streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy 2007;53(6):437-41 (Pubitemid 350085259)
80. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomed 2006;1(2):117-28
81. Lu E, Franzblau S, Onyuksel H, et al. Preparation of aminoglycoside- loaded chitosan nanoparticles using dextran sulphate as a counterion. J Microencapsul 2009;26(4):346-54